학술논문

Global and local ancestry modulate APOE association with Alzheimer’s neuropathology and cognitive outcomes in an admixed sample
Document Type
article
Source
Molecular Psychiatry. 27(11)
Subject
Biomedical and Clinical Sciences
Biological Psychology
Clinical and Health Psychology
Clinical Sciences
Psychology
Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)
Dementia
Acquired Cognitive Impairment
Genetics
Neurodegenerative
Aging
Alzheimer's Disease
Brain Disorders
Neurosciences
Aetiology
2.1 Biological and endogenous factors
Neurological
Humans
Apolipoprotein E4
Alzheimer Disease
Neurofibrillary Tangles
Plaque
Amyloid
Genotype
Biological Factors
Cognition
Biological Sciences
Medical and Health Sciences
Psychology and Cognitive Sciences
Psychiatry
Clinical sciences
Biological psychology
Clinical and health psychology
Language
Abstract
Dementia is more prevalent in Blacks than in Whites, likely due to a combination of environmental and biological factors. Paradoxically, clinical studies suggest an attenuation of APOE ε4 risk of dementia in African ancestry (AFR), but a dearth of neuropathological data preclude the interpretation of the biological factors underlying these findings, including the association between APOE ε4 risk and Alzheimer's disease (AD) pathology, the most frequent cause of dementia. We investigated the interaction between African ancestry, AD-related neuropathology, APOE genotype, and functional cognition in a postmortem sample of 400 individuals with a range of AD pathology severity and lack of comorbid neuropathology from a cohort of community-dwelling, admixed Brazilians. Increasing proportions of African ancestry (AFR) correlated with a lower burden of neuritic plaques (NP). However, for individuals with a severe burden of NP and neurofibrillary tangles (NFT), AFR proportion was associated with worse Clinical Dementia Rating sum of boxes (CDR-SOB). Among APOE ε4 carriers, the association between AFR proportion and CDR-SOB disappeared. APOE local ancestry inference of a subset of 309 individuals revealed that, in APOE ε4 noncarriers, non-European APOE background correlated with lower NP burden and, also, worse cognitive outcomes than European APOE when adjusting by NP burden. Finally, APOE ε4 was associated with worse AD neuropathological burden only in a European APOE background. APOE genotype and its association with AD neuropathology and clinical pattern are highly influenced by ancestry, with AFR associated with lower NP burden and attenuated APOE ε4 risk compared to European ancestry.